Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, Mark Dolev, Shay Menascu, David Magalashvili, Shlomo Flechter, Uri Givon, Diana Guber, Polina Sonis, Rina Zilkha‐Falb, Michael Gurevich
Topics & Concepts
MedicineMultiple sclerosisNatalizumabTeriflunomideFingolimodAlemtuzumabContext (archaeology)CladribineOcrelizumabImmunologyDimethyl fumarateInternal medicineVaccinationImmune systemCross-sectional studyGastroenterologyAntibodyRituximabPathologyBiologyPaleontologySARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders